Corona Remedies IPO GMP History
Corona Remedies IPO has been listed on December 15, 2025 at a listing price of ₹1470, against the issue price of ₹1062 — a gain of ₹408 (+38.42%). The GMP peaked at ₹₹300 on 6 January 2026 and reached a low of ₹300 on 13 January 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Corona Remedies IPO raised ₹655.37 Cr. through its IPO at a price band of ₹₹1,008 – ₹1,062 per share, with a lot size of 14 shares. The IPO was open for subscription from 08 Dec 2025 to 10 Dec 2025.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 13 Jan 2026 | ₹ 300 | ▲ | 484% | ₹ 300 | — |
| 06 Jan 2026 | ₹ ₹300 | — | 28%% | ₹ ₹300 | — |
Corona Remedies IPO dates
Key dates from opening to listing. Today is 30 October.
- Open 08 Dec 2025
- Close 10 Dec 2025
- Allotment 11 Dec 2025
- Refund/credit 12 Dec 2025
- Listing 15 Dec 2025
Corona Remedies IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹1062 |
|---|---|
| Listing gain / loss | +₹408 per share |
| Listing date | 15 Dec, 2025 |
| Actual listing price | ₹1470 (+38.42%) |
Is Corona Remedies IPO GMP reliable?
Grey market premium for Corona Remedies IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Corona Remedies IPO full review for a fundamentals-based assessment before making any grey market trades.
Corona Remedies IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Corona Remedies IPO was Retail: ₹300. This is the fixed amount a grey market buyer pays for your IPO application — regardless of whether you receive allotment.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Corona Remedies IPO
Corona Remedies Limited is an Indian pharmaceutical company established in 2004, focused on developing and marketing a wide range of branded formulations. The company was founded by Chandrakant Patel, who brought extensive experience from the domestic pharma industry. Over the years, Corona Remedies has built a strong presence in therapeutic segments such as women’s healthcare, cardiology, diabetology, pain management and anti-infectives. The company operates with a customer-centric approach, emphasising quality, innovation and accessibility of medicines. It has developed a robust distribution network across India, supported by a large field force that engages with healthcare professionals and institutions. By focusing on niche and high-growth segments, the company has been able to strengthen its brand recall and expand its footprint in the competitive pharmaceutical market.
The company’s product portfolio consists primarily of branded generic medicines, including tablets, capsules, syrups and injectables, catering to both acute and chronic therapies. Corona Remedies follows an asset-light business model, where manufacturing is largely outsourced to WHO-GMP certified third-party facilities while it focuses on marketing, branding and distribution. This allows the company to maintain flexibility and control costs while ensuring consistent product quality. Its strategy revolves around launching differentiated products, building strong doctor relationships and expanding into new therapeutic areas. With a steady focus on research-backed marketing and efficient supply chain management, Corona Remedies aims to sustain long-term growth and strengthen its position in the Indian pharmaceutical industry.
Frequently asked
What is the GMP of Corona Remedies IPO?
The current Grey Market Premium (GMP) of Corona Remedies IPO is ₹ 300.
What is the Kostak Price of Corona Remedies IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Corona Remedies IPO is Retail: ₹300.
What is the Subject to Sauda Price of Corona Remedies IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Corona Remedies IPO?
Corona Remedies IPO listed on December 15, 2025 at ₹1470, against the issue price of ₹1062 — a gain of +38.42%.
How did the GMP of Corona Remedies IPO trend before listing?
The GMP of Corona Remedies IPO was rising in its final days before listing. The GMP peaked at ₹₹300 on 6 January 2026. View the day-wise table above for the complete GMP history.
Explore Corona Remedies IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
